Indolent lymphoma · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Bortezomib and Rituximab (VR) Variant #06 | — | R 64 235 | 35d | ~12.8 mo | — | ~12 | ~R 770 814 PFS proxy · indirect | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~17.7 mo | — | ~3 | ~R 156 PFS proxy · indirect | 4 |
Observation Partial | — | — | — | ~25.4 mo | — | — | — | 8 |
3 of 3 regimens shown